{"id":"NCT02104947","sponsor":"Boehringer Ingelheim","briefTitle":"Reversal of Dabigatran Anticoagulant Effect With Idarucizumab","officialTitle":"A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-06","primaryCompletion":"2016-07-25","completion":"2016-10-20","firstPosted":"2014-04-07","resultsPosted":"2017-08-18","lastUpdate":"2018-01-05"},"enrollment":503,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemorrhage"],"interventions":[{"type":"DRUG","name":"idarucizumab","otherNames":[]}],"arms":[{"label":"idarucizumab","type":"EXPERIMENTAL"}],"summary":"Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.","primaryOutcome":{"measure":"Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT","timeFrame":"from the end of the first infusion up to 4 hours after the last infusion on Day 1","effectByArm":[{"arm":"Idarucizumab (Group A)","deltaMin":100,"sd":null},{"arm":"Idarucizumab (Group B)","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":176,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","India","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["31582135","31050868","30586692","28693366","26095746","26020620"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":160,"n":301},"commonTop":["Constipation","Urinary tract infection","Nausea","Headache","Diarrhoea"]}}